Home/Protocols/Tesamorelin
Protocol Reference
Human trial data

Tesamorelin protocol

Tesamorelin (stabilised GHRH analog). Dosing on this page comes from a published human trial or an approved product label, cited below.

Category
Growth Hormone Axis
Common vials
10 mg
Half-life
~26–38 minutes
Route in the literature
Subcutaneous
Evidence level
Human trial data

How Tesamorelin works

A GHRH analog with a trans-3-hexenoyl group added to the N-terminus, which protects it from degradation by dipeptidyl peptidase-4 and extends its activity relative to unmodified GHRH.

Tesamorelin dosing schedule

From the approved label. Tesamorelin is the strongest-evidenced compound in this category — it holds a current FDA approval, marketed as Egrifta, for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. That specific indication is what the trials studied.

PhaseAmountFrequencyNotes
Approved use2 mgOnce daily, subcutaneousThe single approved amount for the labelled indication.

Study length: Phase 3 trials ran 26 weeks with a 26-week extension. The label notes benefit is not maintained after discontinuation.

Source for this schedule: Tesamorelin (Egrifta) prescribing information, HIV-associated lipodystrophy indication. This reproduces what was administered in that work. It is reference information about a study, not a recommendation, and the trial population, monitoring and endpoints are part of what made it a protocol.

Reconstitution and measurement

This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for Tesamorelin: 10 mg.

Open the Tesamorelin calculator → Unit converter

Storage and stability

Dry powder
Cold, dark and dry. Lyophilized peptide is the stable form — keep it that way until you intend to use it.
After reconstitution
Refrigerate at 2–8 °C, protect from light, and plan around a limited window. Do not freeze a reconstituted vial — freeze-thaw damages peptides.
Mixing
Run bacteriostatic water down the inside wall of the vial rather than onto the powder, then swirl. Never shake.
Inspect before use
A clear solution is expected. Cloudiness or particles mean discard, not use.

Full storage guide → · Cloudy solution?

Reported effects

  • Trial reporting notes injection-site reactions, arthralgia and peripheral oedema.
  • Because it raises IGF-1, the label carries monitoring guidance and contraindications including active malignancy.
  • Visceral fat returned toward baseline after stopping in the extension study.

Sourcing Tesamorelin

Whatever you are working with, the documentation matters more than the price. Ask for a batch certificate of analysis whose lot number matches the vial you actually receive — a COA for a different batch tells you nothing about yours.

Tesamorelin at Summit Research Supply → Grade a COA first

Summit is the supplier we feature and an affiliate link. Our COA checklist applies the same way to any vendor.

Sources and further reading

For laboratory research use only. This page documents what the published literature reports about Tesamorelin. It is not a recommendation, not a treatment plan, and not medical advice. Compounds referenced are sold strictly as research chemicals and are not for human or veterinary use. Some supplier links are affiliate links and may earn us a commission. This never affects tier placement or review conclusions.
Summit Research Supply
Summit Research Supply — COA-verified research peptidesThird-party tested · U.S. fulfillment · new researchers save 10%
Shop →